Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sézary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression

Blood

Volumn 111, Issue 9, 2008, Pages 4780-4787

  Contassot, Emmanuel ^a   Kerl, Katrin ^a   Roques, Stéphanie ^b   Shane, Ryan ^c   Gaide, Olivier ^b   Dupuis, Marc ^d   Rook, Alain H ^c   French, Lars E ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d BioAlliance Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DEATH RECEPTOR 5; DIPEPTIDYL PEPTIDASE IV; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; DEATH RECEPTOR; TNFRSF10B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKOCYTE; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEZARY SYNDROME; SIGNAL TRANSDUCTION; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PATHOLOGY; SKIN TUMOR; T LYMPHOCYTE;

APOPTOSIS; CASE-CONTROL STUDIES; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION; HUMANS; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SEZARY SYNDROME; SKIN NEOPLASMS; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 47149098403     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-08-109074     Document Type: Article

References (44)

1. Rook AH, Vowels BR, Jaworsky C, Singh A, Lessin SR. The immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sezary Tcells. Arch Dermatol. 1993;129:486-489.
2. Vowels BR, Lessin SR, Cassin M, et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol. 1994;103:669-673.
3. Dummer R. Heald PW, Nestle FO, et al. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood. 1996;88:1383-1389.
4. Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol. 1996;35:946-957.
5. Rook AH, Wood GS, Yoo EK, at al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood. 1999;94:902-908.
6. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305-1308.
7. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11:255-260.
8. Lee SH, Shin MS, Park WS, et al. Alterations of Fas (Apo-1/CD95} gene in non-small cell lung cancer. Oncogene. 1999;18:3754-3760.
9. Lee SH, Shin MS, Park WS, et al. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res. 1999;59:3068-3072.
10. Lee SH, Shin MS, Kim HS, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 1999;59:5683-5686.
11. Shin MS. Park WS, Kim SY, et al. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol. 1999;154:1785-1791.
12. Lee SH, Shin MS, Kim HS, et al. Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar. J Invest Dermatol. 2000;114:122-126.
13. Lee SH, Shin MS, Kim HS, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene. 2001;20:399-403.
14. Park WS, Oh RR, Kim YS. et al. Somatic mutations in the death domain of the Fas (Apo-1/CD95) gene in gastric cancer. J Pathol. 2001;193:162-168.
15. Dutton A, O'Neil JD, Milner AE, et al. Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci U S A. 2004;101:6611-6616.
16. Abedini MR, Qiu Q, Yan X, Tsang BK. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene. 2004;23:6997-7004.
17. Irisarri M, Plumas J, Bonnefoix T, et al. Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin's lymphoma B cell line. Leukemia. 2000;14:2149-2158.
18. Korkolopoulou P, Goudopoulou A, Voutsinas G, et al. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology. 2004;63:1198-1204.
19. Lee SH, Kim HS, Kim SY, et al. Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer. APMIS. 2003;111:309-314.
20. Bullani RR, Huard B, Viard-Leveugle I, et al. Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol. 2001;117:360-364.
21. Djerbi M, Screpanti V, Catrina Al, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med. 1999;190:1025-1032.
22. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med. 1999;190:1033-1038.
23. Braun FK, Fecker LF, Schwarz C, et al. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol. 2007;127:2425-2437.
24. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347-1349.
25. Nagata S. Apoptosis by death factor. Cell. 1997; 88:355-365.
26. Ni X, Zhang C, Talpur R, Duvic M. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol. 2005;124:741-750.
27. Dereure O, Portales P, Clot J, Guilhou JJ. Decreased expression of Fas (APO-1/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas. Br J Dermatol. 2000;143:1205-1210.
28. Meech SJ. Edelson R, Walsh P, Norris DA, Duke RC. Reversible resistance to apoptosis in cutaneous Tcell lymphoma. Ann N YAcad Sci. 2001; 941:46-58.
29. Dereure O. Levi E, Vonderheid EC, Kadin ME. Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol. 2002; 118:949-956.
30. van Doom R, Dijkman R, Vermeer MH, Starink TM, Willemze R, Tensen CP. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res. 2002;62:5389-5392.
31. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115:798-812.
32. Zhang XR, Zhang LY, Devadas S, Li L, Keegan AD, Shi YF. Reciprocal expression of TRAILand CD95L in Th1 and Th2 cells: role of apoptosis in T helper subset differentiation. Cell Death Differ. 2003;10:203-210.
33. Conticello C, Pedini F, Zeuner A, et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol. 2004;172:5467-5477.
34. Chuntharapai A, Dodge K, Grimmer K, et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol. 2001;166:4891-4898.
35. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med. 2001;7:954-960.
36. NakaT, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 2002;62:5800-5806.
37. Jin H, Yang R, Fong S, et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res. 2004;64:4900-4905.
38. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factorrelated apoptosis-inducing ligand and CPT-11. Cancer Res. 2003;63:4713-4723.
39. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001; 98:795-804.
40. Nebozhyn M, Loboda A, Kari L, et al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood. 2006;107:3189-3196.
41. Greaney P, Nahimana A, Lagopoulos L, et al. A Fas agonist induces high levels of apoptosis in haematological malignancies. Leuk Res. 2006; 30:415-426.
42. Etter AL, Bassi I, Germain S, et al. The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma. Gynecol Oncol. 2007;107:14-21.
43. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19:2456-2471.
44. Richardson SK, Lin JH, Vittorio CC, et al. High clinical response rate with multimodality immunomodulatory therapy for Sezary syndrome. Clin Lymphoma Myeloma. 2006;7:226-232.